Summary

The Cass Review was set up after referrals to England's child gender service rose sharply and the patients changed to mostly teenage girls, many with autism or mental health problems. Its final report found that care had rested on 'remarkably weak' evidence. Reviews by the University of York could draw no conclusions on how puberty blockers (drugs that pause puberty) affect gender distress or mental health, and found only limited evidence for hormones. Cass recommended whole-person assessment, standard psychological support, blockers only in a research trial, 'extreme caution' with hormones before 18, national review of every medical case, and regional services. It is the most thorough review of its kind, and later reviews agree the evidence is weak. Its methods are disputed, critics and defenders both have stakes, and some advice rests on judgement rather than data.

Key findings

• 2020년 NHS 잉글랜드가 설립하고 2024년 4월 10일 발표된 388쪽의 최종 보고서는 잉글랜드 아동·청소년 성별 서비스에 대해 32개 권고를 담고 있습니다.
• 요크대학교의 사춘기 차단제 검토는 연구 50건(고품질 1건, 중간 25건, 저품질 24건)을 살폈습니다. 성별 고통, 정신 건강, 뇌 발달에 대한 효과에 관해서는 결론을 내릴 수 없으며 뼈 건강과 키가 영향을 받을 수 있다고 했습니다.
• 요크의 반대 성 호르몬 검토는 연구 53건(고품질 1건, 중간 33건, 저품질 19건)을 살폈습니다. 치료 중 정신 건강이 좋아질 수 있다는 중간 품질의 근거는 있었지만, 다른 효과에 관해서는 결론을 내릴 수 없었습니다.
• 검토는 자폐 및 유사한 상태 확인과 정신 건강 평가를 포함한 전인적 평가와, 고통과 다른 상태에 대한 표준적이고 검증된 대화 치료 및 약물을 권고합니다.
• 사춘기 차단제는 연구 안에서만 줘야 합니다(NHS 잉글랜드는 시험을 추진했습니다). 16세부터의 호르몬은 ‘극도의 신중함’과 18세까지 기다리지 않는 명확한 이유가 필요하며, 의학적 치료의 모든 사례는 국가 전문가 패널로 가야 합니다.
• 검토는 WPATH(세계트랜스젠더보건전문가협회)를 포함한 지침이 면밀하게 만들어지지 않았다고 판단했습니다. NHS 성인 성별 클리닉 7곳 중 6곳이 장기 결과 연구를 위한 자료 공유를 거부했으며, 검토는 참여하도록 지시해야 한다고 말합니다.
• 어린 아동의 사회적 전환(새 이름, 옷, 대명사)을 결정하는 가족은 일찍 경험 많은 임상의를 만나야 하고, 모든 청소년은 의학적 치료 전에 생식 능력 상담과 난자 또는 정자 보관을 제안받아야 합니다.
• 보고서는 예일대 Integrity Project(McNamara 등, 2024)와 동료 심사 논문(Noone 등, 2025)에서 비판받았습니다. Archives of Disease in Childhood(Cheung 등, 2025)와 Journal of Sex & Marital Therapy(McDeavitt 등, 2025)에서는 옹호되었습니다.

Abstract

1. The aim of this Review is to make recommendations that ensure that children and young people who are questioning their gender identity or experiencing gender dysphoria receive a high standard of care. Care that meets their needs, is safe, holistic and effective. At its heart are vulnerable children and young people and an NHS service unable to cope with the demand. 2. Yet from the start, the Review stepped into an arena where there were strong and widely divergent opinions unsupported by adequate evidence. The surrounding noise and increasingly toxic, ideological and polarised public debate has made the work of the Review significantly harder and does nothing to serve the children and young people who may already be subject to significant minority stress. 3. Within this context the Review set out to understand the reasons for the growth in referrals and the changing epidemiology, and to identify the clinical approach and service model that would best serve this population. 4. There are conflicting views about the clinical approach, with expectation at times being far from usual clinical practice. This has made some clinicians fearful of working with gender-questioning young people, despite their presentation being similar to many children and young people presenting to other NHS services. 5. Although some think the clinical approach should be based on a social justice model, the NHS works in an evidence-based way. Whilst navigating a way through the surrounding ‘culture war’, the Review has been acutely and increasingly aware of the need for evidence to support its thinking and ultimately the final recommendations made in this report. 6. When the Review started, the evidence base, particularly in relation to the use of puberty blockers and masculinising/feminising hormones, had already been shown to be weak. There was, and remains, a lot of misinformation easily accessible online, with opposing sides of the debate pointing to research to justify a position, regardless of the quality of the studies.

Conclusion

The Cass Review concludes that children and young people questioning their gender identity or experiencing gender dysphoria require a high standard of care that is safe, holistic, and evidence-based. The Review found that the evidence base for medical interventions, particularly puberty blockers and masculinising/feminising hormones, is weak, and that clinical practice has been complicated by a toxic, polarised public debate. The ten key recommendations focus on: (1) ensuring services meet standard NHS care standards with clear clinical leadership; (2) implementing holistic assessment frameworks including screening for neurodevelopmental conditions and mental health; (3) using standard evidence-based psychological and psychopharmacological treatments; (4) ensuring early clinical involvement in decisions about social transition of pre-pubertal children; (5-6) establishing robust research and data collection programmes to improve the evidence base; (7) requiring long-standing gender incongruence as essential but not sufficient for medical treatment; (8) exercising extreme caution in prescribing hormones from age 16; (9) requiring national Multi Disciplinary Team review for all medical treatment cases; and (10) offering fertility counselling and preservation before any medical pathway. The Review emphasises that the NHS must work in an evidence-based way rather than following a social justice model, and that the needs of vulnerable children and young people must be prioritised over ideological positions.